Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 31;8(4):433-437.
doi: 10.4103/apjon.apjon-2120. eCollection 2021 Jul-Aug.

Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study

Xinjuan Huang  1 , Xuying Li  1 , Jinhua Li  1 , Lu Luo  2 , Hongyun Chen  3 , Yan Tan  1 , Tao Wei  1 , Xingfeng Li  4 , Liwen Guo  4 , Jing Cheng  4
Affiliations

Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study

Xinjuan Huang et al. Asia Pac J Oncol Nurs. .

Abstract

Objective: This study aimed to assess the occurrence of chemotherapy-induced nausea and vomiting (CINV) in acute phase (24 h after chemotherapy) and delayed phase (2-5 days after chemotherapy) after standard antiemetic therapy and to explore the risk factors of CINV in the acute and delayed phases.

Methods: This prospective and observational study analyzed the data of 400 breast cancer patients scheduled for chemotherapy in two hospitals. The self-report survey was developed to assess the occurrence of CINV and their associated factors. On day 2 and day 6 of chemotherapy, CINV was evaluated by the Multinational Association of Supportive Care in Cancer Antiemetic Tool (MAT). The incidence of acute and delayed CINV was expressed as frequency and percentage.

Results: Among 400 patients, 29.8% and 23.5% experienced acute and delayed CINV, respectively. Logistic regression analysis showed that the risk factors associated with acute CINV included pain/insomnia, history of CINV, and highly emetogenic chemotherapy. The history of motion sickness (MS), history of CINV, number of chemotherapy cycles completed, and the incidence of acute CINV were significant risk factors for delayed CINV (all P < 0.05).

Conclusions: The results of this study are helpful for nurses to identify high-risk patients with CINV, formulate effective treatment plans, and reduce the incidence of CINV.

Keywords: Antiemetic guidelines; breast cancer; chemotherapy-induced nausea and vomiting; risk factors.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Patients' flowchart
See this image and copyright information in PMC

References

    1. Barrios CH, Reinert T, Werutsky G. Global breast cancer research: Moving forward. Am Soc Clin Oncol Educ Book. 2018;38:441–50. - PubMed
    1. Gibbons A, Groarke A. Coping with chemotherapy for breast cancer: Asking women what works. Eur J Oncol Nurs. 2018;35:85–91. - PubMed
    1. Jodar M, Jacquin JP, Vallée J. Perception of adverse reactions of chemotherapy and hormone therapy by women treated for breast cancer. Therapie. 2016;71:263–73. - PubMed
    1. David S, Berger MJ, Barbour S, Bergsbaken J, Brandt D, Brown GE, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis,[EB/OL] Antiemesis (Version 2. 2020) [Last accessed on 2020 Apr 23]. Available from: http://guide.medlive.cn/
    1. Chan VT, Yeo W. Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer (Dove Med Press) 2011;3:151–60. - PMC - PubMed

LinkOut - more resources